Resources

Not all lifestyle change programs are created equal. Learn why most diet and exercise programs fail and how you can help your members succeed with sustainable lifestyle change.

Get the results of a new survey of 60 senior health plan leaders to understand how the GLP-1 cost crisis is evolving and how they are handling it.

The first known study to demonstrate sustained health improvements after GLP-1 deprescription.

60 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders weigh in on the growing GLP-1 cost crisis

Find out why leaders are saying goodbye to management programs that lack outcomes and ROI, and making the switch to reversal for diabetes and obesity.

Whether your organization has felt the tidal wave of GLP-1 claims yet or not - it's coming. Learn about a new set of options to navigate this spike.

GLP-1 drugs are hitting the market with new indications but are rising utilization and prices widening health disparities?

A new survey of 80 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders shines a light on the growing GLP-1 cost crisis

Digital healthcare has long touted a promise to address health disparities, but is the new wave of solutions making any headway in closing health equity gaps in type 2 diabetes? Research says yes.

More than 150 million Americans depend on employer-sponsored insurance (ESI) for their health care, but the health outcomes of ESI enrollees has not been well understood given historical data gaps and limitations in analyzing health outcomes across race, ethnicity and income.

Clinical validation, ROI and sustainability - is it possible to have all three? Learn how to separate fact from fiction and identify vendors delivering best-in-class outcomes.

How we treat diabetes is changing. Reversal - not management - is the new gold standard. Learn about the benefits of diabetes reversal, beyond metabolic health.